Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Germany , Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles...

Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to drive future upside. Despite market concerns over GLP-1 drugs and recent share declines, FMS is positioned for double-digit EPS growth and offers a well-covered 3-4% yield.

Fresenius Medical Care AG ( FMS ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Call Participants Oliver Metzger - ODDO BHF Corporate & Markets, Research Divisio...

Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7% Reported operating income grew by 3%, reported net income3 by 29% Net leverage ratio further improved to 2.6x, in parallel to sh...

Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take hold.

Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation highlights the association between HDF and reduced risk of cardiovascular and fluid-related hospitalization outcomes.

Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year end BAD HOMBURG, Germany , Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for indi...

Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022 Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value...